Europe Single-Cell Sequencing and Spatial Transcriptomics Market: Focus on Product, Technology, Workflow, Application, and Country - Analysis and Forecast, 2026-2036

The Europe single-cell sequencing and spatial transcriptomics market, valued at $789.3 million in 2026, is projected to grow substantially, reaching $3,067.6 million by 2036, with a compound annual growth rate (CAGR) of 14.54% during the forecast period from 2026 to 2036.

The Europe market is growing as researchers seek to characterize cellular heterogeneity while preserving the spatial context of molecular activity within tissues. Single-cell sequencing analyzes genomic, transcriptomic, epigenomic, and multiomic features at individual-cell resolution, while spatial transcriptomics maps gene expression to tissue locations. Together, these technologies support research into tumor microenvironments, immune behavior, neurological disorders, development, treatment response, and disease progression. Their use across oncology, immunology, neuroscience, cell and gene therapy, biomarker discovery, and translational research is supporting demand from academic institutes, biopharmaceutical companies, contract research organizations, hospitals, and laboratories.

Market advances are focused on spatial multiomics, higher throughput, automation, FFPE compatibility, and AI-enabled bioinformatics. Providers are combining RNA, DNA, proteins, chromatin accessibility, imaging, and tissue morphology within integrated workflows. Platforms are improving sensitivity, resolution, multiplexing, sample compatibility, and efficiency, while cloud analytics, automated segmentation, AI-supported annotation, and visualization tools simplify complex data analysis. These developments are positioning single-cell and spatial technologies as important enablers of precision medicine and biomedical research across Europe.

Industrial Impact

The Europe single-cell sequencing and spatial transcriptomics market is becoming increasingly innovation-driven and platform-integrated as life science tools, sequencing, spatial biology, imaging, and bioinformatics companies expand across connected sample-to-insight workflows. Market participants are moving beyond standalone instruments and assays toward ecosystems that combine sample preparation, cell isolation, library preparation, sequencing, spatial profiling, imaging, consumables, software, and data interpretation. Product differentiation is increasingly based on throughput, spatial resolution, plex level, sensitivity, FFPE compatibility, automation, reproducibility, and the ability to integrate multiple molecular layers. Established and specialized companies are strengthening their positions through product launches, acquisitions, collaborations, and workflow integration. Competition is increasing around AI-enabled analysis, FFPE compatibility, automation, and regional service support. Overall, industry impact is shifting toward scalable spatial multiomics and integrated solutions for oncology, immunology, neuroscience, cell therapy, and translational research.

Market Segmentation

Segmentation 1: By Product

• Single-Cell Sequencing
  • Instruments
  • Consumables
  • Software
  
  
• Spatial Transcriptomics
  • Instruments
  • Consumables
  • Software
  
  

Consumables Segment to Dominate the Europe Single-Cell Sequencing and Spatial Transcriptomics Market (by Product)

In 2025, based on product, consumables accounted for the largest share of the single-cell sequencing segment of the Europe single-cell sequencing and spatial transcriptomics market. This leadership has been primarily driven by the repeated use of kits, reagents, enzymes, buffers, cartridges, probes, barcodes, slides, and other materials across cell isolation, sample preparation, library preparation, amplification, sequencing, imaging, and quality-control workflows. Unlike instruments, which generally involve one-time capital investment and longer replacement cycles, consumables must be replenished for each sample and experimental run. Demand is further supported by the growing number of single-cell and spatial studies, increasing sample throughput, and the use of specialized assay-specific reagents required to generate sensitive and reproducible data.

Segmentation 2: By Technology

• Single-Cell Sequencing
  • Single-Cell RNA Sequencing (scRNA-seq)
  • Single-Cell DNA Sequencing
  • Single-Cell Multi-Omics Sequencing
  • Others
  
  
• Spatial Transcriptomics
  • Sequencing-Based Spatial Transcriptomics
  • Imaging-Based Spatial Transcriptomics
  • In Situ Hybridization-Based Technologies
  • Others
  
  

Sequencing-Based Spatial Transcriptomics Segment by spatial transcriptomics to Dominate the Europe Single-Cell Sequencing and Spatial Transcriptomics Market (by Technology)

In 2025, on the basis of spatial transcriptomics technology, sequencing-based spatial transcriptomics accounted for the largest share of the Europe market. Its leadership has been supported by its ability to provide high-throughput, transcriptome-wide gene-expression analysis while preserving the spatial location of molecular signals within tissue samples. The technology is increasingly used in oncology, neuroscience, developmental biology, immunology, biomarker discovery, and tissue-atlas research, where understanding the relationship between cell identity and tissue architecture is essential. Compatibility with established next-generation sequencing infrastructure also enables laboratories to integrate spatial assays into existing sequencing workflows. Improvements in resolution, capture efficiency, FFPE compatibility, and bioinformatics integration are expected to support continued market growth.

Segmentation 3: By Workflow

• Single-Cell Sequencing
  • Sample Collection and Preservation
  • Cell Isolation, Cell Capture/Partitioning
  • Library Preparation
  • Sequencing
  • Data Processing
  • Bioinformatics Analysis, Interpretation, and Validation
  
  
• Spatial Transcriptomics
  • Imaging/Hybridization/Sequencing
  • Spatial Data Analysis
  • Tissue Sectioning and Preparation
  • Others
  
  

Library Preparation Segment by single-cell sequencing to Dominate the Europe Single-Cell Sequencing and Spatial Transcriptomics Market (by Workflow)

In 2025, on the basis of the single-cell sequencing workflow, library preparation accounted for the largest share of the Europe market. Library preparation is an essential step that converts isolated cellular RNA or DNA into sequencing-ready libraries through processes such as reverse transcription, amplification, indexing, barcoding, and quality control. It represents a recurring requirement for each sample and experiment and frequently depends on platform-specific kits and reagents. The segment is supported by increasing adoption of scRNA-seq, scDNA-seq, immune profiling, chromatin-accessibility analysis, and single-cell multiomics. Bioinformatics analysis, interpretation, and validation is expected to grow rapidly as laboratories require scalable tools to process high-dimensional datasets, identify cell populations, integrate multiple modalities, and generate biologically meaningful results.

Segmentation 4: By Application

• Single-Cell Sequencing
  • Oncology
  • Immunology
  • Neurology
  • Drug Discovery and Development
  • Infectious Disease Research
  • Stem Cell Biology
  • Cell and Gene Therapy Research
  • Developmental Biology
  • Stem Cell Research
  • Reproductive Biology
  • Other Applications
  
  
• Spatial Transcriptomics
  • Oncology
  • Translational Research
  • Immunology
  • Tissue Atlas and Cell Mapping Studies
  • Drug Discovery and Development
  • Neurology
  • Developmental Biology
  • Stem Cell Research
  • Infectious Disease Research
  • Other Applications
  
  

Oncology Segment to Dominate the Europe Single-Cell Sequencing and Spatial Transcriptomics Market (by Application)

In 2025, on the basis of application, oncology accounted for the largest share of the Europe single-cell sequencing and spatial transcriptomics market. Its leadership has been supported by the extensive use of these technologies to study intratumoral heterogeneity, rare malignant-cell populations, immune infiltration, tumor evolution, treatment resistance, metastatic progression, and the spatial organization of the tumor microenvironment. Single-cell sequencing helps identify molecular differences among cancer-cell and immune-cell populations, while spatial transcriptomics preserves information on where these cells are located and how they interact within tissue. These capabilities support biomarker discovery, therapeutic-target identification, patient stratification research, immuno-oncology, and translational studies. Cell and gene therapy research is expected to expand rapidly due to increasing demand for cellular characterization, safety assessment, treatment-response analysis, and product quality control.

Segmentation 5: By End User

• Research and Academic Institutes
• Biopharmaceutical and Biotechnology Companies
• Contract Research Organizations
• Others (Hospitals, Clinics, and Diagnostic Laboratories)

Research and Academic Institutes Segment to Dominate the Europe Single-Cell Sequencing and Spatial Transcriptomics Market (by End User)

In 2025, on the basis of end user, research and academic institutes accounted for the largest share of the Europe market. This has been supported by their strong involvement in basic research, disease biology, cell-atlas initiatives, developmental studies, biomarker discovery, tumor-microenvironment analysis, immunology, neuroscience, and translational research. Universities, public research organizations, medical research centers, and genomics core facilities are among the earliest adopters of high-resolution single-cell and spatial technologies because they frequently conduct exploratory studies requiring advanced analytical depth. Public research funding and collaborative European initiatives also support access to sequencing, microscopy, computational infrastructure, and specialized expertise. Contract research organizations are expected to grow rapidly as pharmaceutical and biotechnology companies increasingly outsource complex single-cell and spatial studies to specialist service providers.

Segmentation 6: By Country

• U.K.
• Germany
• France
• Italy
• Spain
• Rest-of-Europe

Germany to Hold a Significant Position in the Europe Single-Cell Sequencing and Spatial Transcriptomics Market (by Country)

In 2025, Germany is expected to lead the Europe single-cell sequencing and spatial transcriptomics market due to its broad research infrastructure, strong public funding, large network of universities and research institutes, biopharmaceutical activity, and specialized single-cell and spatial biology programs. Demand is supported by genomics centers, cancer research institutes, core facilities, and collaborative research networks using high-resolution molecular profiling. The U.K. remains another major market, supported by its mature genomics ecosystem, NHS-linked research, national sequencing initiatives, and strong academic base. France, Italy, Spain, and Rest-of-Europe contribute through genomics programs, research consortia, cancer institutes, and expanding spatial biology adoption. Regional growth will depend on funding, core-facility access, bioinformatics capacity, standardization, and clinical translation.

Recent Developments in the Single-Cell Sequencing and Spatial Transcriptomics Market

• In June 2026, 10x Genomics, Inc. acquired Proteintech Genomics to expand its proteomics capabilities and strengthen integrated RNA and protein analysis across single-cell and spatial workflows.
• In June 2026, Illumina, Inc. launched StrataMap Spatial Solution, an end-to-end spatial whole-transcriptome research solution designed to provide spatial biology at true single-cell resolution.
• In April 2026, Bruker Spatial Biology introduced integrated workflows linking GeoMx Digital Spatial Profiler with CellScape XR and CellScape XR with CosMx Spatial Molecular Imager, supporting connected multiomic tissue-profiling studies.
• In March 2026, MGI Tech Co., Ltd. announced the acquisition of STOmics and CycloneSEQ, bringing spatial biology and nanopore sequencing technologies in-house and strengthening its integrated omics portfolio.

Demand - Drivers, Challenges, and Opportunities

Market Drivers

Growing Focus on Precision Medicine

The increasing focus on precision medicine is driving demand for single-cell sequencing and spatial transcriptomics because these technologies reveal molecular and cellular differences that bulk analysis can overlook. Single-cell approaches allow researchers to identify rare cell populations, characterize disease-associated cell states, and evaluate heterogeneous treatment responses, while spatial methods show how cells are organized and interact within intact tissue. These capabilities are particularly valuable in oncology, immunology, neuroscience, rare diseases, and cell and gene therapy research. Commercial opportunity is therefore shifting from standalone data generation toward integrated workflows that support biomarker discovery, patient-stratification research, therapeutic-target identification, and translational decision-making. Vendors that can provide reproducible assays, scalable analytics, and clinically relevant outputs are expected to benefit as precision-medicine programs expand across Europe.

Growing Investments in National Genomics Programs and Research Infrastructure

Continued investment in genomics programs, biomedical research centers, sequencing facilities, biobanks, digital pathology, and computational infrastructure is expanding the addressable market for single-cell and spatial technologies. Europe has a strong network of universities, government-funded institutes, cancer centers, genomics core facilities, and cross-border research consortia that support high-resolution molecular profiling. These investments improve access to instruments, specialized personnel, high-performance computing, and standardized research workflows. They also create opportunities for platform vendors, reagent suppliers, software companies, and service providers to participate in collaborative studies and long-term research programs. However, commercial impact will vary by country because funding intensity, procurement cycles, core-facility availability, and bioinformatics capacity remain uneven across the region.

Market Challenges

Complex Data Analysis and Shortage of Bioinformatics Expertise

The complexity of data analysis represents a major restraint because single-cell sequencing and spatial transcriptomics generate large, high-dimensional datasets that require specialized computational infrastructure and expertise. Researchers must manage quality control, normalization, batch correction, cell clustering, annotation, image segmentation, spatial mapping, multimodal integration, visualization, and biological interpretation. Differences among platforms, sample types, protocols, and analytical pipelines can also affect reproducibility and cross-study comparability. Academic laboratories and smaller biotechnology companies may face particular difficulty recruiting bioinformaticians and maintaining scalable computing environments. This challenge is creating demand for automated pipelines, cloud-based software, AI-enabled annotation, standardized analysis methods, and user-friendly interfaces, but adoption may remain constrained where budgets and specialist skills are limited.

Market Opportunities

Clinical Translation of Single-Cell Sequencing and Spatial Transcriptomics

Clinical translation represents a significant long-term opportunity as these technologies move beyond exploratory research toward biomarker development, pathology-integrated analysis, patient stratification, therapy-response assessment, and clinical-trial support. Spatial profiling may be particularly valuable in oncology because it connects molecular expression with tissue morphology and cellular interactions, while single-cell analysis can identify clinically relevant subpopulations that influence prognosis or treatment response. Commercial growth will depend on workflow standardization, analytical and clinical validation, reproducibility, quality management, regulatory compliance, and the generation of evidence demonstrating clinical utility. Vendors that can develop clinically validated assays, FFPE-compatible workflows, automated software, pathology integration, and interpretable reporting solutions are likely to gain a stronger position as adoption expands from research laboratories toward translational and selected clinical settings.

How can this report add value to an organization?

Product/Innovation Strategy: The Europe single-cell sequencing and spatial transcriptomics market has been segmented across product, technology, workflow, application, end user, and country. This segmentation helps organizations understand demand across instruments, consumables, and software and assess adoption patterns across scRNA-seq, scDNA-seq, single-cell multiomics, sequencing-based spatial transcriptomics, imaging-based spatial transcriptomics, and in situ hybridization-based technologies. It also supports product planning by identifying the importance of automation, FFPE compatibility, higher throughput, spatial resolution, multiomic integration, and bioinformatics.

Growth/Marketing Strategy: The market is being driven by precision-medicine research, expanding genomics infrastructure, oncology and immunology applications, cell and gene therapy development, and increasing interest in high-resolution tissue analysis. This report helps organizations assess market-entry opportunities, identify high-potential customer groups, and prioritize commercial strategies across academic institutes, biopharmaceutical companies, contract research organizations, hospitals, clinics, and diagnostic laboratories. It also supports country-level opportunity assessment by highlighting differences in research funding, genomics infrastructure, clinical translation, procurement environments, and bioinformatics capacity across the U.K., Germany, France, Italy, Spain, and Rest-of-Europe.

Competitive Strategy: The Europe market includes sequencing companies, single-cell platform developers, spatial biology innovators, imaging providers, reagent suppliers, bioinformatics companies, and integrated life science technology vendors. The report helps organizations benchmark competitor presence, assess platform and workflow positioning, identify gaps across technology and application segments, and evaluate opportunities for partnerships, acquisitions, regional service expansion, and portfolio development. Competitive assessment also highlights the growing importance of end-to-end workflows, AI-enabled analysis, recurring consumables, local support capabilities, and integration with sequencing, microscopy, pathology, and cloud infrastructure.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

• Years from 2024 to 2036 have been considered for the Europe market size estimation; 2025 has been considered as the base year, and 2026 to 2036 as the forecast period.
• The market revenue has been estimated to be the same as the companies’ net revenue distribution. All the numbers have been adjusted to one digit after the decimal for report presentation reasons. However, the real figures have been utilized for compound annual growth rate (CAGR) estimation. The CAGR has been calculated for the period from 2026 to 2036.
• In the study, the primary respondents' verification has been considered to finalize the estimated market for single-cell sequencing and spatial transcriptomics.
• The latest annual reports of each market player have been taken into consideration for market revenue calculation.
• Market strategies and developments of key players have been considered for the calculation of the sub-segment split.
• The base currency considered for the market analysis is US$. Currencies other than the US$ have been converted to the US$ for all statistical calculations, considering the average conversion rate for that particular year.
• The currency conversion rate has been taken from the historical exchange rate of the Oanda website or from the annual reports of the respective company, if stated.

Primary Research

The primary sources involve experts and stakeholders across life sciences, genomics, spatial biology, molecular diagnostics, biopharmaceutical research, and healthcare. Participants include platform manufacturers, reagent and software vendors, genomics core facilities, pharmaceutical and biotechnology companies, academic institutes, contract research organizations, hospitals, laboratories, distributors, and regulatory consultants. CEOs, product leaders, application scientists, laboratory heads, principal investigators, procurement managers, and bioinformatics professionals have been interviewed to verify qualitative and quantitative findings.

The key data points taken from the primary sources include:

• validation and triangulation of all the numbers and graphs
• validation of report segmentations and key qualitative findings
• understanding the competitive landscape and business model
• current and proposed production values of a product by market players
• validation of the numbers of different segments of the market in focus
• percentage split of individual markets for regional analysis

Secondary Research

Open Sources

• Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
• Annual reports, SEC filings, and investors’ presentations of the leading market players
• Company websites and a detailed study of their product portfolio
• Gold standard magazines, journals, white papers, press releases, and news articles
• Paid databases

The key data points taken from the secondary sources include:

• segmentations and percentage shares
• data for market value
• key industry trends of the top players in the market
• qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
• quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from an analysis of company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• 10x Genomics, Inc.
• Illumina, Inc.
• Standard BioTools Inc.
• Mission Bio
• Bruker Corporation
• Singleron Biotechnologies
• Quanterix Corporation
• Vizgen Corporation
• Waters Corporation
• MGI Tech Co., Ltd.
• Oxford Nanopore Technologies plc
• QIAGEN N.V.
• Bio-Rad Laboratories, Inc.
• Ultima Genomics, Inc.